Document Type : Original Article
Authors
1 Assistant Professor, Department of Biochemistry, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran
2 Assistant Professor, Department of Nanobiotechnology, New Technologies Research Group, Pasteur Institute of Iran
3 Professor, Department of Biochemistry, Pasteur Institute of Iran
4 Professor, Department of Nanobiotechnology, New Technologies Research Group, Pasteur Institute of Iran, Tehran, Iran
Abstract
Introduction: In recent years, due to the spread of drug resistance in the Plasmodium parasite and the shortcomings of anti-malarial drugs, the use of liposome-based nanomedicines in treating malaria has garnered significant attention. This research studied the effect of liposomes containing the antimalarial compound Eosin B on the Plasmodium berghei parasite in murine malaria.
Methods: Liposomes containing Eosin B were prepared using cholesterol in the presence of Eosin B via solvent evaporation. Eosin B, Eosin B liposome, drug solvent, drug-free liposomes, and control drugs were administered to infected mice. The percentage of parasite inhibitory activity was evaluated using Peter’s test. In the in vitro model, the Plasmodium falciparum parasite was first cultured, and the survival percentage of the parasite in each group was investigated using the parasite lactate dehydrogenase test.
Results: In each test group, the percentage of parasitemia under the effect of the Eosin B liposome was lower than that of Eosin B alone, and the inhibition percentage was significantly higher (P<0.05). Also, the survival percentage of the parasite in the in vitro model was lower in each group under the effect of the Eosin B liposome compared to Eosin B alone.
Conclusion: Liposomes containing Eosin B can increase efficacy in the mouse malaria model and reduce the drug’s dose. Considering the reduction of drug dosage in treating malaria by the Eosin B liposome, using this liposome drug might be beneficial.
Keywords
- Organization WH. World Malaria reports 2020–20 years of global progress and challenges. Geneva: World Health Organization;
- Fujioka H, Aikawa M. Structure and life cycle. Chem Immunol. 2002;80:1-26.
- Anamika J, Nikhar V, Laxmikant G, Priya S, Sonal V, Vyas SP. Nanobiotechnological modules as molecular target tracker for the treatment and prevention of malaria: options and opportunity. Drug Deliv Transl Res. 2020;10(4):1095-110.
- Crommelin DJA, van Hoogevest P, Storm G. The role of liposomes in clinical nanomedicine development. What now? Now what? J Control Release. 2020;318:256-63.
- Suresh M, Jeevanandam J, Chan YS, Danquah MK, Kalaiarasi J. Opportunities for metal oxide nanoparticles as a potential mosquitocide. Bionanoscience. 2020;10(1):292-310.
- Rajendran V, Singh C, Ghosh PC. Improved efficacy of doxycycline in liposomes against Plasmodium falciparum in culture and Plasmodium berghei infection in mice. Can J Physiol Pharmacol. 2018;96(11):1145-52.
- Raza M, Bharti H, Singal A, Nag A, Ghosh PC. Long circulatory liposomal maduramicin inhibits the growth of Plasmodium falciparum blood stages in culture and cures murine models of experimental malaria. Nanoscale. 2018;10(28):13773-91.
- Atreya CE, Johnson EF, Irwin JJ, Dow A, Massimine KM, Coppens I, et al. A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase. J Biol Chem. 2003;278(16):14092-100.
- Zamani Z, Tafreshi AS, Nahrevanian H, Lame-Rad B, Pourfallah F, Eslamifar H, et al. Efficacy of eosin B as a new antimalarial drug in a murine model. Malar Res Treat. 2012;2012:381724.
- Najafzadeh M, Bakhshandeh H, Zamani Z, Movahedi M, Atyabi SM. Preparation, characterization, and evaluation of eosin B-loaded nano-liposomes for growth inhibition of Plasmodium falciparum. Parasitol Res. 2022;121(1):383-93.
- Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg. 1993;48(2):205-10.
- Massimine KM, McIntosh MT, Doan LT, Atreya CE, Gromer S, Sirawaraporn W, et al. Eosin B as a novel antimalarial agent for drug-resistant Plasmodium falciparum. Antimicrob Agents Chemother. 2006;50(9):3132-41.
- Sadeghi Tafreshi A, Zamani Z, Sabbaghian M, Khavari-Nejad RA, Arjmand M, Sadeghi S, et al. A Metabolomic Investigation of the Effect of Eosin B on Game-tocyte of Plasmodium falciparum Using 1HNMR Spectroscopy. Iran J Parasitol. 2019;14(4):592-603.
- Sadeghi S, Valadkhani Z, Tafreshi AS, Arjmand M, Nahravanian H, Vahabi F, et al. A Study of Synergy of Combination of Eosin B with Chloroquine, Artemisinin, and Sulphadoxine-Pyrimethamine on Plasmodium falciparum In Vitro and Plasmodium berghei In Vivo. J Trop Med. 2020;2020:3013701.
- West African Network for Clinical Trials of Antimalarial D. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet. 2018;391(10128):1378-90.
- Tiwari S, Goyal AK, Mishra N, Khatri K, Vaidya B, Mehta A, et al. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine. J Control Release. 2009;140(2):157-65.
- Peeters PA, Huiskamp CW, Eling WM, Crommelin DJ. Chloroquine containing liposomes in the chemotherapy of murine malaria. Parasitology. 1989;98 Pt 3:381-6.
- Ismail M, Ling L, Du Y, Yao C, Li X. Liposomes of dimeric artesunate phospholipid: A combination of dimerization and self-assembly to combat malaria. Biomaterials. 2018;163:76-87.
- Moles E, Urban P, Jimenez-Diaz MB, Viera-Morilla S, Angulo-Barturen I, Busquets MA, et al. Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy. J Control Release. 2015;210:217-29.
)